CL-218,872 EU

6 - 52

Discover CL-218,872 – The Next Generation Sedative

Maak kennis met CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Dit product is ook verkrijgbaar in Capsule en Druppels voor een eenvoudiger onderzoek.

Alle producten uit de EU-detailhandel kunnen alleen naar EU-landen worden verzonden.

Alle designer drugs die op deze website worden verkocht zijn bedoeld voor onderzoek en forensische toepassingen.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Dosering en toediening:

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Waarom kopen? CL-218,872 EU from RECHEMCO?

★ We hebben een lange handelsgeschiedenis in de markt, dus je profiteert van onze ervaring.
★ CL-218,872 werd getest en geverifieerd.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

Wat u ontvangt bij aankoop CL-218,872 EU from RECHEMCO?

- Een verzegelde zak van aluminiumfolie met de hoogste kwaliteit CL-218,872 EU
• White powder
• 98-99% Purity

Hoeveelheid

50mg, 100mg, 250mg, 500mg, 1g

Beoordelingen

Er zijn nog geen beoordelingen.

Wees de eerste om “CL-218,872 EU” te beoordelen

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *

SPIN OM TE WINNEN!

  • Beproef uw geluk en win een kortingscouponcode
  • 1 gratis spin elke 15 dagen
  • Niet valsspelen! Gebruik alleen uw echte e-mailadres.
  • LET OP: De couponcode is 7 dagen geldig.
Beproef je geluk!
Nooit
Later herinneren
Geen dank.